Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Have documented diagnosis of GD.
Have a TSH value < 0.1 mIU/L as assessed by the local laboratory at the Screening Visit.
Meet one of the following at the Screening Visit:
Have been on ATD for ≥ 3 months in the period immediately preceding the Screening Visit and both of the following:
Have been on ATD for ≥ 6 months in the period immediately preceding the Screening Visit and all of the following:
Additional inclusion criteria are defined in the protocol.
Exclusion criteria
Additional exclusion criteria are defined in the protocol.
Primary purpose
Allocation
Interventional model
Masking
240 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Central Study Contact
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal